Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.68 |
| ▸ | ITGAV | P06756 | 20/20 | 0.68 |
| ▸ | ITGB6 | P18564 | 16/20 | 0.68 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.56 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.56 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.56 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.56 |
| ▸ | ITGA8 | P53708 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL244091 | 0.85 | ITGB3 (0.91) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL27561816 | 0.85 | ITGB3 (0.75) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL27555011 | 0.81 | ITGB3 (0.60) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6224489 | 0.81 | ITGB3 (1.00) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL27484813 | 0.79 | ITGB3 (0.47) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7835721 | 0.78 | ITGB3 (0.91) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6840650 | 0.77 | ITGB3 (0.49) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6841294 | 0.76 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6888885 | 0.75 | ITGB3 (0.48) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL6810083 | 0.75 | ITGB3 (0.91) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | GENESTE HERVE (DE) | 2012-01-05 | — | — | US | disclosed |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | BASF AKTIENGESELLSCHAFT (DE) | 2009-12-17 | — | — | US | disclosed |
| EP-1239877-B1 | COMPOSITION COMPRISING A TNF-ALPHA INHIBITOR AND AN INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONIST | ABBOTT GMBH & CO KG (DE) | 2008-01-09 | — | — | EP | disclosed |
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | GENESTE HERVE | 2006-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060159678-A1 | Modulators of cytokine mediated signaling pathways and integrin alphabeta3 receptor antagonists for combination therapy | ITGB3, IL6ST, IL1RN | ITGB3 1/4885ITGAV 11/4885ITGB6 14/4885 |
| US-20090311266-A1 | Inhibitors of the endothelin signalling pathway and alphavbeta3 integrin receptor antagonists for combination therapy | EDNRB, EDNRA, ITGB3 | ITGB3 3/4885ITGAV 4/4885ITGB6 38/4885 |
| US-20120003229-A1 | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN ALPHAVBETA3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY | ITGB3, ITGAV, ITGB1 | ITGB3 1/4885ITGAV 2/4885ITGB6 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.